MedKoo product information:

 Aclarubicin Hydrochloride

aclarubicin is an oligosaccharide anthracycline antineoplastic antibiotic isolated from the bacterium Streptomyces galilaeus. Aclarubicin intercalates into DNA and interacts with topoisomerases I and II, thereby inhibiting DNA replication and repair and RNA and protein synthesis. Aclarubicin is antagonistic to other agents that inhibit topoisomerase II, such as etoposide, teniposide and amsacrine. This agent is less cardiotoxic than doxorubicin and daunorubicin. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus).

 1: Shin DH, Choi KS, Park SA, Cho BS, Lee HS, Ryu JS, Kim TY, Lee CK, Song S, Chung YB. Extensive intracellular accumulation of ID-6105, a novel anthracycline, in SK-OV-3 ovarian cancer cells. Arch Pharm Res. 2008 Oct;31(10):1355-61. Epub 2008 Oct 29. PubMed PMID: 18958428.

2: Swift LP, Cutts SM, Nudelman A, Levovich I, Rephaeli A, Phillips DR. The cardio-protecting agent and topoisomerase II catalytic inhibitor sobuzoxane enhances doxorubicin-DNA adduct mediated cytotoxicity. Cancer Chemother Pharmacol. 2008 Apr;61(5):739-49. Epub 2007 Jun 27. PubMed PMID: 17594094.

3: Zhu H, Huang M, Yang F, Chen Y, Miao ZH, Qian XH, Xu YF, Qin YX, Luo HB, Shen X, Geng MY, Cai YJ, Ding J. R16, a novel amonafide analogue, induces apoptosis and G2-M arrest via poisoning topoisomerase II. Mol Cancer Ther. 2007 Feb;6(2):484-95. PubMed PMID: 17308047.

4: Koceva-Chyła A, Wiecławska B, Jóźwiak Z, Bryszewska M. Combined effect of low-power laser irradiation and anthraquinone anticancer drug aclarubicin on survival of immortalized cells: Comparison with mitoxantrone. Cell Biol Int. 2006 Aug;30(8):645-52. Epub 2006 Apr 25. PubMed PMID: 16857396.

5: Goodell JR, Madhok AA, Hiasa H, Ferguson DM. Synthesis and evaluation of acridine- and acridone-based anti-herpes agents with topoisomerase activity. Bioorg Med Chem. 2006 Aug 15;14(16):5467-80. Epub 2006 May 19. PubMed PMID: 16713270.

6: Liao Z, Thibaut L, Jobson A, Pommier Y. Inhibition of human tyrosyl-DNA phosphodiesterase by aminoglycoside antibiotics and ribosome inhibitors. Mol Pharmacol. 2006 Jul;70(1):366-72. Epub 2006 Apr 17. PubMed PMID: 16618796.

7: Koceva-Chyła A, Jedrzejczak M, Skierski J, Kania K, Jóźwiak Z. Mechanisms of induction of apoptosis by anthraquinone anticancer drugs aclarubicin and mitoxantrone in comparison with doxorubicin: relation to drug cytotoxicity and caspase-3 activation. Apoptosis. 2005 Dec;10(6):1497-514. PubMed PMID: 16215684.

8: Wang T, Chen FY, Gu CH, Zhong H, Teng Y, Ouyang RR. [Transfection of HL-60 cells with CYP3A5 gene induces drug-resistant phenotype]. Zhonghua Zhong Liu Za Zhi. 2005 Aug;27(8):461-4. Chinese. PubMed PMID: 16188140.

9: Ryu JS, Lee HS, Hong YS, Lee JJ, Sohn UD, Kim TY. In vivo antitumor efficacy and cardiotoxicity of novel anthracycline ID6105 (11-hydroxy-aclacinomycin X, Hyrubicin). Cancer Chemother Pharmacol. 2006 Jun;57(6):811-8. Epub 2005 Sep 21. Erratum in: Cancer Chemother Pharmacol. 2007 Feb;59(2):283-4. PubMed PMID: 16175393.

10: Lehmann M, Vilar Kde S, Franco A, Reguly ML, Rodrigues de Andrade HH. Activity of topoisomerase inhibitors daunorubicin, idarubicin, and aclarubicin in the Drosophila Somatic Mutation and Recombination Test. Environ Mol Mutagen. 2004;43(4):250-7. PubMed PMID: 15141364.

11: Addadi-Rebbah S, Poitevin S, Fourre N, Polette M, Garnotel R, Jeannesson P. Assessment of the antiinvasive potential of the anthracycline aclacinomycin (Aclarubicin) in a human fibrosarcoma cell line. Int J Oncol. 2004 Jun;24(6):1607-15. PubMed PMID: 15138606.

12: Furuchi T, Nitta K, Takahashi T, Naganuma A. Overexpression of Ssl2p confers resistance to adriamycin and actinomycin D in Saccharomyces cerevisiae. Biochem Biophys Res Commun. 2004 Feb 13;314(3):844-8. PubMed PMID: 14741713.

13: Menna P, Salvatorelli E, Giampietro R, Liberi G, Teodori G, Calafiore AM, Minotti G. Doxorubicin-dependent reduction of ferrylmyoglobin and inhibition of lipid peroxidation: implications for cardiotoxicity of anticancer anthracyclines. Chem Res Toxicol. 2002 Sep;15(9):1179-89. PubMed PMID: 12230412.

14: Barret JM, Kruczynski A, Etiévant C, Hill BT. Synergistic effects of F 11782, a novel dual inhibitor of topoisomerases I and II, in combination with other anticancer agents. Cancer Chemother Pharmacol. 2002 Jun;49(6):479-86. Epub 2002 Apr 6. PubMed PMID: 12107553.

15: Akanitapichat P, Lowden CT, Bastow KF. 1,3-Dihydroxyacridone derivatives as inhibitors of herpes virus replication. Antiviral Res. 2000 Feb;45(2):123-34. PubMed PMID: 10809021.

16: Jedrzejczak M, Koceva-Chyła A, Gwoździński K, Jóźwiak Z. Changes in plasma membrane fluidity of immortal rodent cells induced by anticancer drugs doxorubicin, aclarubicin and mitoxantrone. Cell Biol Int. 1999;23(7):497-506. PubMed PMID: 10728787.

17: Metodiewa D, Kochman A, Skolimowski J, Koceva-Chyła A. TTT, a novel free radical spin trap, induces apoptosis in sarcoma Yoshida cells in vivo: comparative investigations of its cytotoxicity in vitro. Anticancer Res. 1999 Jul-Aug;19(4B):3343-8. PubMed PMID: 10652631.

18: Morgan SE, Cadena RS, Raimondi SC, Beck WT. Selection of human leukemic CEM cells for resistance to the DNA topoisomerase II catalytic inhibitor ICRF-187 results in increased levels of topoisomerase IIalpha and altered G(2)/M checkpoint and apoptotic responses. Mol Pharmacol. 2000 Feb;57(2):296-307. PubMed PMID: 10648639.

19: Metodiewa D, Koceva-Chyła A, Kochman A, Skolimowski J, Jóźwiak Z. Antiproliferative and cytotoxic effects of N,N-diethylaminoethyl ethers of flavanone oximes: a comparison with anthracycline(s), anthraquinone and nitroxides action. Anticancer Res. 1999 Mar-Apr;19(2A):1255-60. PubMed PMID: 10368685.

20: Wakazono Y, Kataoka A, Fusaoka T, Tunamoto K. [Successful treatment with idarubicin in a pediatric case of t(8;21) acute myelogenous leukemia with additional chromosomal abnormalities at relapse]. Rinsho Ketsueki. 1998 Jul;39(7):499-505. Japanese. PubMed PMID: 9750457.

21: Hiwasa T, Tokita H, Sakiyama S, Nakagaware A. Enhancement of chemosensitivity toward anticancer drugs by high expression of caspase-1 in NIH 3T3 cells. Anticancer Drugs. 1998 Jan;9(1):82-7. PubMed PMID: 9491796.

22: Nitiss JL, Pourquier P, Pommier Y. Aclacinomycin A stabilizes topoisomerase I covalent complexes. Cancer Res. 1997 Oct 15;57(20):4564-9. PubMed PMID: 9377570.

23: Hiwasa T, Tokita H, Ike Y. Differential chemosensitivity in oncogene-transformed cells. J Exp Ther Oncol. 1996 May;1(3):162-70. PubMed PMID: 9414400.

24: Sehested M, Jensen PB. Mapping of DNA topoisomerase II poisons (etoposide, clerocidin) and catalytic inhibitors (aclarubicin, ICRF-187) to four distinct steps in the topoisomerase II catalytic cycle. Biochem Pharmacol. 1996 Apr 12;51(7):879-86. PubMed PMID: 8651936.

25: Ito H. [Experimental study and clinical application of a new combination chemotherapy with cis-platinum, adriamycin and carboquone in patients with advanced prostate cancer]. Nippon Ika Daigaku Zasshi. 1995 Oct;62(5):456-68. Japanese. PubMed PMID: 7499463.

26: Zhao X, Lu D, Jiang S, Mao C, Fan Y, An C, Li Z. Interaction between intercalation type anticancer drugs and DNA studied by ultraviolet resonance Raman spectroscopy. Sci China B. 1995 May;38(5):555-63. PubMed PMID: 7626197.

27: Takehara M, Hayakawa O, Kudo R. [Experimental and clinical study on chemotherapy for cervical adenocarcinoma]. Nippon Sanka Fujinka Gakkai Zasshi. 1995 Apr;47(4):405-12. Japanese. PubMed PMID: 7537322.

28: Yamanaka T, Hishinuma A. [Different effects of anticancer drugs on two human thyroid cell lines with different stages of differentiation]. Nippon Naibunpi Gakkai Zasshi. 1995 Jan 20;71(1):73-86. Japanese. PubMed PMID: 7895867.

29: Dong J, Naito M, Tatsuta T, Seimiya H, Johdo O, Tsuruo T. Difference between the resistance mechanisms of aclacinomycin- and adriamycin-resistant P388 cell lines. Oncol Res. 1995;7(5):245-52. PubMed PMID: 8534930.

30: Okuyama T, Maehara Y, Endo K, Baba H, Adachi Y, Kuwano M, Sugimachi K. Expression of glutathione S-transferase-pi and sensitivity of human gastric cancer cells to cisplatin. Cancer. 1994 Aug 15;74(4):1230-6. PubMed PMID: 8055443.

31: Takeishi Y, Sukekawa H, Sakurai T, Saito H, Nishimura S, Shibu T, Sasaki Y, Tomoike H. Noninvasive identification of anthracycline cardiotoxicity: comparison of 123I-MIBG and 123I-BMIPP imaging. Ann Nucl Med. 1994 Aug;8(3):177-82. PubMed PMID: 7811559.

32: Jensen PB, Sørensen BS, Sehested M, Grue P, Demant EJ, Hansen HH. Targeting the cytotoxicity of topoisomerase II-directed epipodophyllotoxins to tumor cells in acidic environments. Cancer Res. 1994 Jun 1;54(11):2959-63. PubMed PMID: 8187081.

33: Sørensen BS, Jensen PB, Sehested M, Jensen PS, Kjeldsen E, Nielsen OF, Alsner J. Antagonistic effect of aclarubicin on camptothecin induced cytotoxicity: role of topoisomerase I. Biochem Pharmacol. 1994 Jun 1;47(11):2105-10. PubMed PMID: 8010996.

34: Konno T, Kai Y, Yamashita R, Nagamitsu A, Kimura M. Targeted chemotherapy for unresectable primary and metastatic liver cancer. Acta Oncol. 1994;33(2):133-7. PubMed PMID: 7515628.

35: Temma K, Akera T, Chugun A, Kondo H, Hagane K, Hirano S. Comparison of cardiac actions of doxorubicin, pirarubicin and aclarubicin in isolated guinea-pig heart. Eur J Pharmacol. 1993 Apr 6;234(2-3):173-81. PubMed PMID: 8482324.

36: Miyazaki M, Suzuki H, Itoh H, Kaiho T, Nakajima T, Andoh K, Anbiru S, Ohtawa S, Ogata A, Yasuda N, et al. Portal vein infusion of cancer chemotherapeutic agent emulsified with Lipiodol in regenerating liver after partial hepatectomy in rats. Res Exp Med (Berl). 1993;193(4):231-40. PubMed PMID: 8235076.

37: Kanemoto N, Aoki N, Goto Y. Electrical alternans of the T-U wave without change in the QRS complex. Intern Med. 1992 Apr;31(4):486-8. PubMed PMID: 1633354.

38: Suzuki H, Miyazaki M, Iinuma K, Udagawa I, Koshikawa H, Ito H, Okui K. [Enhancement of selective drug accumulation and retention in normal and regenerating liver by the use of lipiodol in portal venous infusion in rats]. Nippon Geka Gakkai Zasshi. 1991 Oct;92(10):1480-5. Japanese. PubMed PMID: 1660095.

39: Ohyama S, Yonemura Y, Kinoshita K, Ninomiya I, Tugawa K, Kimura H, Miyazaki I, Tanaka M, Endo Y, Sasaki T. [Chemosensitivity test for gastric cancer by in vitro MTT assay]. Gan To Kagaku Ryoho. 1991 Aug;18(10):1593-7. Japanese. PubMed PMID: 1908213.

40: Watanabe T, Nakasaki H, Mitomi T. Measurement of cross-reactive properties of adriamycin derivatives by the inhibition enzyme-linked immunosorbent assay for adriamycin. Tokai J Exp Clin Med. 1990 Jul;15(4):327-34. PubMed PMID: 2130540.

41: Jensen PB, Sørensen BS, Demant EJ, Sehested M, Jensen PS, Vindeløv L, Hansen HH. Antagonistic effect of aclarubicin on the cytotoxicity of etoposide and 4'-(9-acridinylamino)methanesulfon-m-anisidide in human small cell lung cancer cell lines and on topoisomerase II-mediated DNA cleavage. Cancer Res. 1990 Jun 1;50(11):3311-6. PubMed PMID: 2159380.

42: Asaga T, Kobayashi O, Masuzawa C, Motohashi H, Okamoto T. [Extended radical mastectomy using preoperative local injection of activated carbon particle adsorbing aclarubicin (ACR-CH)]. Nippon Geka Gakkai Zasshi. 1990 Mar;91(3):313-9. Japanese. PubMed PMID: 2359386.

43: Miyamoto Y, Oda T, Maeda H. Comparison of the cytotoxic effects of the high- and low-molecular-weight anticancer agents on multidrug-resistant Chinese hamster ovary cells in vitro. Cancer Res. 1990 Mar 1;50(5):1571-5. PubMed PMID: 2137371.

44: Yoshikawa H, Nakao Y, Takada K, Muranishi S, Wada R, Tabata Y, Hyon SH, Ikada Y. Targeted and sustained delivery of aclarubicin to lymphatics by lactic acid-oligomer microsphere in rat. Chem Pharm Bull (Tokyo). 1989 Mar;37(3):802-4. PubMed PMID: 2752497.

45: Ahmed K, Turk JL. Effect of anticancer agents neothramycin, aclacinomycin, FK-565 and FK-156 on the release of interleukin-2 and interleukin-1 in vitro. Cancer Immunol Immunother. 1989;28(2):87-92. PubMed PMID: 2783891.

46: Umeki S, Niki Y, Soejima R. Anticancer chemotherapy accelerates scalp hair loss with no androgenic involvement. Chemotherapy. 1989;35(1):54-7. PubMed PMID: 2721290.

47: Hassan HT, Rees JK. Low concentrations of cytosine arabinoside, 6-thioguanine, actinomycin-D and aclacinomycin A stimulates the differentiation of normal human marrow myeloid progenitor cells. Med Oncol Tumor Pharmacother. 1989;6(3):213-7. PubMed PMID: 2615525.

48: Konno T, Maeda H. [Targeting cancer chemotherapy using lipiodol as a carrier of anticancer drugs for hepatocellular carcinoma]. Gan To Kagaku Ryoho. 1988 Apr;15(4 Pt 2-1):1043-50. Review. Japanese. PubMed PMID: 2839112.

49: Fujiwara K. [Development and application of enzyme immunoassays for anticancer drugs]. Tanpakushitsu Kakusan Koso. 1987 Sep;(31 Suppl):99-108. Japanese. PubMed PMID: 3122270.

50: Lin J, Sartorelli AC. Stimulation by interferon of the differentiation of human promyelocytic leukemia (HL-60) cells produced by retinoic acid and actinomycin D. J Interferon Res. 1987 Aug;7(4):379-87. PubMed PMID: 2444656.

51: Konno T. [Targeting chemotherapy of hepatocellular carcinoma by arterial administration of anticancer agents dissolved in lipiodol]. Gan To Kagaku Ryoho. 1987 Feb;14(2):373-80. Japanese. PubMed PMID: 3028275.

52: Afanas'ev IB, Polozova NI, Kuprianova NS, Gunar VI. Mechanism of the interaction of superoxide ion and ascorbate with anthracycline antibiotics. Free Radic Res Commun. 1987;3(1-5):141-50. PubMed PMID: 2854525.

53: Wadler S, Fuks JZ, Wiernik PH. Phase I and II agents in cancer therapy: I. Anthracyclines and related compounds. J Clin Pharmacol. 1986 Sep-Oct;26(7):491-509. Review. PubMed PMID: 2944917.

54: Hagiwara A, Ahn T, Ueda T, Iwamoto A, Ueda T, Torii T, Takahashi T. Anticancer agents adsorbed by activated carbon particles, a new form of dosage enhancing efficacy on lymphnodal metastases. Anticancer Res. 1986 Sep-Oct;6(5):1005-8. PubMed PMID: 2432828.

55: Komiyama T, Kikuchi T, Sugiura Y. Interactions of anticancer quinone drugs, aclacinomycin A, adriamycin, carbazilquinone, and mitomycin C, with NADPH-cytochrome P-450 reductase, xanthine oxidase and oxygen. J Pharmacobiodyn. 1986 Aug;9(8):651-64. PubMed PMID: 3023600.

56: Fujita H, Ogawa K, Tone H, Iguchi H, Shomura T, Murata S. Pharmacokinetics of doxorubicin, (2"R)-4'-O-tetrahydropyranyl-adriamycin and aclarubicin. Jpn J Antibiot. 1986 May;39(5):1321-36. PubMed PMID: 3463778.

57: Hiraki S, Ohnoshi T, Kishimoto N, Mori K, Nishii K, Yonei T, Yamashita H, Kimura I. [Sensitivity testing of anticancer drugs using the human tumor clonogenic assay]. Gan To Kagaku Ryoho. 1986 Apr;13(4 Pt 2):1208-13. Japanese. PubMed PMID: 3729443.

58: Miyamoto H. In vitro chemosensitivity and radiosensitivity of an adriamycin-resistant subline of human small cell lung cancer cells. Acta Med Okayama. 1986 Apr;40(2):75-81. PubMed PMID: 3012966.

59: Kohno T, Matsutani M, Hoshino T, Takakura K. [Effects of anticancer drugs on multicellular spheroid of 9L rat brain tumor]. No To Shinkei. 1985 Oct;37(10):991-7. Japanese. PubMed PMID: 3865669.

60: Gupta RS. Cross-resistance of vinblastine- and taxol-resistant mutants of Chinese hamster ovary cells to other anticancer drugs. Cancer Treat Rep. 1985 May;69(5):515-21. PubMed PMID: 2860971.

61: Sohda M, Fujiwara K, Saikusa H, Kitagawa T, Nakamura N, Hara K, Tone H. Sensitive enzyme immunoassay for the quantification of aclacinomycin A using beta-D-galactosidase as a label. Cancer Chemother Pharmacol. 1985;14(1):53-8. PubMed PMID: 3917377.

62: Takahashi I, Oda Y, Lai M, Fukumoto M, Nishimura M, Yorimitsu S, Kitajima K, Kimura I. Interaction between human lymphoblastoid interferon and chemotherapeutic agents in vitro. Acta Med Okayama. 1984 Dec;38(6):501-4. PubMed PMID: 6335349.

63: Konno T, Iwai K, Maki S, Tashiro S, Miyauchi Y, Maeda H, Yokoyama I. [Arterial administration of SMANCS and other antitumor agents dissolved in lipiodol for various malignant solid tumors]. Nippon Geka Gakkai Zasshi. 1984 Sep;85(9):1151-6. Japanese. PubMed PMID: 6095018.

64: Tanaka N. [Mechanism of action and resistance of antineoplastic agents]. Gan To Kagaku Ryoho. 1983 Nov;10(11):2245-51. Review. Japanese. PubMed PMID: 6195971.

65: Namba M, Yamamoto S, Tanaka H, Kanamori T, Nobuhara M, Kimoto T. [Potentiation of the cytotoxic effects of various anticancer drugs by interferon on human neoplastic cells (HeLa) in culture]. Gan To Kagaku Ryoho. 1983 May;10(5):1308-12. Japanese. PubMed PMID: 6191681.

66: Komiyama T, Kikuchi T, Sugiura Y. Generation of hydroxyl radical by anticancer quinone drugs, carbazilquinone, mitomycin C, aclacinomycin A and adriamycin, in the presence of NADPH-cytochrome P-450 reductase. Biochem Pharmacol. 1982 Nov 15;31(22):3651-6. PubMed PMID: 6295407.